Optimising the CYP3A4 Ontogeny in Paediatric PBPK Models - are we there yet?

Topics Covered:
• Optimizing Hepatic CYP3A4 ontogeny
• Optimizing Intestinal CYP3A4 ontogeny
• Using available paediatric clinical data for model verification
• Future research
Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,300 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
Please visit us at www.certara.com/